AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11346839 — intervention group
Group type: EXPERIMENTAL
Intervention: Vignette case history of an amputation patient varying in age (36yr, 76yr), gender (male, female), and behavior (ideal, depressed, noncompliant) followed by the Professional Bias Questionnaire (PBQ).
Number of subjects: 974
Study 11346839 — intervention group
Group type: EXPERIMENTAL
Intervention: Professional Bias Questionnaire (PBQ) assessing responses to the vignette.
Number of subjects: 974
Study 9580385 — intervention group
Group type: EXPERIMENTAL
Intervention: CVP + IFN (3 MU/m2 three times a week for 3 months)
Number of subjects: 155
Study 9580385 — intervention group
Group type: COMPARATOR
Intervention: CVP alone
Number of subjects: 155
Study 9580385 — intervention group
Group type: EXPERIMENTAL
Intervention: CVP + IFN
Number of subjects: 155
Study 9580385 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance IFN
Number of subjects: 155
Study 8040634 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention with prominent dialogue, social interactions, and scaffolded instruction
Number of subjects: 109
Study 8040634 — intervention group
Group type: COMPARATOR
Intervention: Other intervention (not specified)
Number of subjects: 109
Study 3050905 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen 50 mg preoperatively
Number of subjects: 40
Study 3050905 — intervention group
Group type: EXPERIMENTAL
Intervention: ACC-30 preoperatively
Number of subjects: 40
Study 3050905 — intervention group
Group type: COMPARATOR
Intervention: Flurbiprofen postoperatively
Number of subjects: 40
Study 3050905 — intervention group
Group type: COMPARATOR
Intervention: ACC-30 postoperatively
Number of subjects: 40
Study 31393082 — intervention group
Group type: EXPERIMENTAL
Intervention: Phospho-histone H2AX (γH2AX) levels
Number of subjects: 60
Study 29120838 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine HPV testing
Number of subjects: 217
Study 29120838 — intervention group
Group type: COMPARATOR
Intervention: Pap smear
Number of subjects: 217
Study 25782644 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg escitalopram daily from preanesthesia to postoperative day 6
Number of subjects: 120
Study 25782644 — intervention group
Group type: COMPARATOR
Intervention: Placebo daily from preanesthesia to postoperative day 6
Number of subjects: 120
Study 25782644 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 120
Study 23407221 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 months of isoniazid plus rifampicin (3RH)
Number of subjects: 590
Study 23407221 — intervention group
Group type: COMPARATOR
Intervention: 6 months of isoniazid (6H)
Number of subjects: 590
Study 23407221 — intervention group
Group type: EXPERIMENTAL
Intervention: Both 3RH and 6H
Number of subjects: 590
Study 23407221 — intervention group
Group type: EXPERIMENTAL
Intervention: 3RH
Number of subjects: 590
Study 23407221 — intervention group
Group type: COMPARATOR
Intervention: 6H
Number of subjects: 590
Study 21087452 — intervention group
Group type: EXPERIMENTAL
Intervention: Vienna nomogram (group A)
Number of subjects: 303
Study 21087452 — intervention group
Group type: COMPARATOR
Intervention: 8-core prostate biopsy (group B)
Number of subjects: 303
Study 21087452 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 303
Study 19531592 — intervention group
Group type: EXPERIMENTAL
Intervention: PPAR alpha agonist (20 microg/d GW590735)
Number of subjects: 31
Study 19531592 — intervention group
Group type: EXPERIMENTAL
Intervention: PPAR delta agonist (10 mg/d GW501516)
Number of subjects: 31
Study 19531592 — intervention group
Group type: COMPARATOR
Intervention: Ketogenic diet
Number of subjects: 31
Study 19531592 — intervention group
Group type: COMPARATOR
Intervention: PPAR gamma agonist (rosiglitazone)
Number of subjects: 31
Study 19531592 — intervention group
Group type: COMPARATOR
Intervention: Fasting and refeeding
Number of subjects: 31
Study 17569044 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinorelbine (VRL) 20 mg m(‐2) i.v. on day 1, Docetaxel (DCT) 60 mg m(‐2) on day 1, Oral VRL 60 mg m(‐2) on day 15 every 3 weeks
Number of subjects: 30
Study 17569044 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinorelbine (VRL) 20 mg m(‐2) i.v. with Docetaxel (DCT) 60 mg m(‐2) on day 1, Oral VRL 60 mg m(‐2) on day 15 every 3 weeks
Number of subjects: 30
Study 17569044 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 30
Study 15104197 — intervention group
Group type: EXPERIMENTAL
Intervention: Cutaneous allergy tests
Number of subjects: 45
Study 15104197 — intervention group
Group type: EXPERIMENTAL
Intervention: Histopathologic and immunohistochemical studies
Number of subjects: 45
Study 15104197 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunoblot analysis
Number of subjects: 45
Study 15104197 — intervention group
Group type: EXPERIMENTAL
Intervention: IgE recognition of flea proteins
Number of subjects: 45
Study 11208496 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug I (propafenone, sotalol, or disopyramide)
Number of subjects: 58
Study 11208496 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug II (second antiarrhythmic drug)
Number of subjects: 58
Study 11208496 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone (Drug III)
Number of subjects: 58
Study 11208496 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone (after first unsuccessful CV)
Number of subjects: 58
Study 9563814 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine (LTG)
Number of subjects: 12
Study 8172365 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 200 micrograms
Number of subjects: 38
Study 8172365 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 400 micrograms
Number of subjects: 38
Study 8172365 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 30369161 — intervention group
Group type: EXPERIMENTAL
Intervention: Ningmitai capsules (4 capsules per time, 3 times per day)
Number of subjects: 269
Study 30369161 — intervention group
Group type: COMPARATOR
Intervention: Control group (antibiotics or sodium diclofenac suppository on demand)
Number of subjects: 269
Study 27898683 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-day NIAAA hazardous drinking
Number of subjects: 700
Study 27898683 — intervention group
Group type: COMPARATOR
Intervention: No drinking
Number of subjects: 700
Study 27898683 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate drinking
Number of subjects: 700
Study 27898683 — intervention group
Group type: COMPARATOR
Intervention: Injection drug use, polysubstance use, environmental risk exposures (past incarceration, police involvement, selling sex, HIV stigma)
Number of subjects: 700
Study 24804483 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed electromagnetic fields (PEMFs)
Number of subjects: 0
Study 24804483 — intervention group
Group type: COMPARATOR
Intervention: Cyclical alendronate
Number of subjects: 0
Study 22421008 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month therapy group
Number of subjects: 156
Study 22421008 — intervention group
Group type: COMPARATOR
Intervention: 12-month therapy group
Number of subjects: 156
Study 20167686 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute water loading
Number of subjects: 23
Study 20167686 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic water loading
Number of subjects: 23
Study 20167686 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased water intake of 3 L per day
Number of subjects: 23
Study 19074351 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil administration
Number of subjects: 0
Study 19074351 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 17190281 — intervention group
Group type: EXPERIMENTAL
Intervention: Anal dilators
Number of subjects: 40
Study 17190281 — intervention group
Group type: COMPARATOR
Intervention: Topical nitroderivatives
Number of subjects: 40
Study 12881373 — intervention group
Group type: EXPERIMENTAL
Intervention: Mammography screening
Number of subjects: 5
Study 12881373 — intervention group
Group type: COMPARATOR
Intervention: Control arm (no mammography screening)
Number of subjects: 5
Study 11203857 — intervention group
Group type: EXPERIMENTAL
Intervention: IPS Empress inlays and onlays
Number of subjects: 34
Study 8626044 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycine-extended gastrin-17 infusion at three consecutive dose rates
Number of subjects: 8
Study 8626044 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycine-extended gastrin-17 infusion
Number of subjects: 8
Study 8626044 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycine-extended gastrin-17 infusion during constant-rate infusion after a protein meal
Number of subjects: 8
Study 8626044 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycine-extended gastrin-17
Number of subjects: 8
Study 1575169 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril, 20 mg, administered in the evening (10 PM)
Number of subjects: 18
Study 1575169 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril, 20 mg, administered in the morning (8 AM)
Number of subjects: 18
Study 1575169 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 3918178 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate 50 mg daily for 6 to 9 months
Number of subjects: 101
Study 3918178 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 101
Study 30614649 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg of methylprednisolone
Number of subjects: 306
Study 30614649 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 306
Study 29872803 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g high MW (HMW) barley beta-glucan
Number of subjects: 30
Study 29872803 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 g low MW (LMW) barley beta-glucan
Number of subjects: 30
Study 29872803 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g LMW barley beta-glucan
Number of subjects: 30
Study 29872803 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 30
Study 27048871 — intervention group
Group type: COMPARATOR
Intervention: Dry nasal low-flow oxygen (dry-NLFO)
Number of subjects: 18
Study 27048871 — intervention group
Group type: COMPARATOR
Intervention: Humidified nasal low-flow oxygen (humidified-NLFO)
Number of subjects: 18
Study 25254489 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose of N-acetylcysteine (NAC) and saline
Number of subjects: 500
Study 25254489 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (NaHCO3) and saline
Number of subjects: 500
Study 25254489 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments (NAC and NaHCO3) and saline
Number of subjects: 500
Study 25254489 — intervention group
Group type: COMPARATOR
Intervention: Saline only
Number of subjects: 500
Study 21717449 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemestane 25 mg daily
Number of subjects: 103
Study 21717449 — intervention group
Group type: COMPARATOR
Intervention: Anastrozole 1 mg daily
Number of subjects: 103
Study 21717449 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemestane after crossover
Number of subjects: 103
Study 21717449 — intervention group
Group type: COMPARATOR
Intervention: Anastrozole after crossover
Number of subjects: 103
Study 19521657 — intervention group
Group type: EXPERIMENTAL
Intervention: Unipedal standing exercise (6-month program: standing on a single foot for 1 min per leg, 3 times per day)
Number of subjects: 94
Study 19521657 — intervention group
Group type: EXPERIMENTAL
Intervention: Unipedal standing exercise (in participants aged >/=70 years, n = 20)
Number of subjects: 94
Study 19521657 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise, n = 11)
Number of subjects: 94
Study 17579345 — intervention group
Group type: EXPERIMENTAL
Intervention: Total mesorectal excision with preoperative radiotherapy (PRT)
Number of subjects: 399
Study 17579345 — intervention group
Group type: COMPARATOR
Intervention: Total mesorectal excision without preoperative radiotherapy (PRT)
Number of subjects: 399
Study 16318132 — intervention group
Group type: EXPERIMENTAL
Intervention: Double moxibustion at Yifeng (TE 17) combined with electroacupuncture
Number of subjects: 87
Study 16318132 — intervention group
Group type: COMPARATOR
Intervention: Simple electroacupuncture
Number of subjects: 87
Study 12197847 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple‐plus‐yogurt group (AB‐Yogurt)
Number of subjects: 160
Study 12197847 — intervention group
Group type: COMPARATOR
Intervention: Triple‐only group
Number of subjects: 160
Study 9798043 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillin therapy (intramuscular benzylpenicillin, 50,000 U/[kg.d] for 5 days and then oral penicillin, 50 mg/[kg.d] for 5 days)
Number of subjects: 44
Study 9798043 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin therapy (50 mg/[kg.d] orally for 10 days)
Number of subjects: 44
Study 7719245 — intervention group
Group type: EXPERIMENTAL
Intervention: all‐trans retinoic acid (ATRA)
Number of subjects: 0
Study 7719245 — intervention group
Group type: EXPERIMENTAL
Intervention: ATRA
Number of subjects: 0
Study 7719245 — intervention group
Group type: EXPERIMENTAL
Intervention: PML‐RAR alpha
Number of subjects: 0
Study 7719245 — intervention group
Group type: EXPERIMENTAL
Intervention: ATRA treatment
Number of subjects: 0
Study 7719245 — intervention group
Group type: EXPERIMENTAL
Intervention: PML‐RAR alpha and PLZF‐RAR alpha
Number of subjects: 0
Study 2673129 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenelzine sulfate
Number of subjects: 51
Study 2673129 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline hydrochloride
Number of subjects: 51
Study 2673129 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 103469 — intervention group
Group type: EXPERIMENTAL
Intervention: HC 20-511 (Ketotifen)
Number of subjects: 14
Study 103469 — intervention group
Group type: EXPERIMENTAL
Intervention: clemastine
Number of subjects: 14
Study 103469 — intervention group
Group type: EXPERIMENTAL
Intervention: DSCG
Number of subjects: 14
Study 103469 — intervention group
Group type: EXPERIMENTAL
Intervention: beclomethasone dipropionate
Number of subjects: 14
Study 31812999 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress scripts
Number of subjects: 28
Study 31812999 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma scripts
Number of subjects: 28
Study 31812999 — intervention group
Group type: COMPARATOR
Intervention: Neutral scripts
Number of subjects: 28
Study 29969577 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial-body cryostimulation (PBC): 3 min at ‐160 °C
Number of subjects: 9
Study 29969577 — intervention group
Group type: COMPARATOR
Intervention: Passive recovery at 21 °C
Number of subjects: 9
Study 28107336 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-affirmations
Number of subjects: 140
Study 28107336 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-affirmations and nature sounds
Number of subjects: 140
Study 28107336 — intervention group
Group type: EXPERIMENTAL
Intervention: Nature sounds
Number of subjects: 140
Study 28107336 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 140
Study 25629739 — intervention group
Group type: EXPERIMENTAL
Intervention: Less-tight control (target diastolic blood pressure, 100 mm Hg)
Number of subjects: 987
Study 25629739 — intervention group
Group type: COMPARATOR
Intervention: Tight control (target diastolic blood pressure, 85 mm Hg)
Number of subjects: 987
Study 25629739 — intervention group
Group type: EXPERIMENTAL
Intervention: Less-tight control
Number of subjects: 987
Study 25629739 — intervention group
Group type: COMPARATOR
Intervention: Tight control
Number of subjects: 987
Study 22899580 — intervention group
Group type: EXPERIMENTAL
Intervention: High CLLU1 expression
Number of subjects: 515
Study 22899580 — intervention group
Group type: COMPARATOR
Intervention: Low CLLU1 expression
Number of subjects: 515
Study 22899580 — intervention group
Group type: EXPERIMENTAL
Intervention: High CLLU1 expression among patients with mutated IGHV genes
Number of subjects: 515
Study 22899580 — intervention group
Group type: COMPARATOR
Intervention: Low CLLU1 expression among patients with mutated IGHV genes
Number of subjects: 515
Study 20496177 — intervention group
Group type: EXPERIMENTAL
Intervention: BAK-PLO (baclofen 10 mg, amitriptyline HCL 40 mg, ketamine 20 mg in pluronic lecithin organogel)
Number of subjects: 208
Study 20496177 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLO)
Number of subjects: 208
Study 19807931 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal subcutaneous injection of rhFSH (Puregon 300)
Number of subjects: 12
Study 19807931 — intervention group
Group type: COMPARATOR
Intervention: Abdominal subcutaneous injection of rhFSH (Puregon 300)
Number of subjects: 12
Study 16396729 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiropractic manipulation
Number of subjects: 70
Study 12641809 — intervention group
Group type: EXPERIMENTAL
Intervention: Informational support about postnatal depression
Number of subjects: 70
Study 12641809 — intervention group
Group type: COMPARATOR
Intervention: Control group (no informational support)
Number of subjects: 70
Study 11032098 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 100 mg BID
Number of subjects: 0
Study 11032098 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg BID
Number of subjects: 0
Study 11032098 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 400 mg BID
Number of subjects: 0
Study 9545890 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyract/PSA
Number of subjects: 4
Study 9545890 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyract/P&B 2.0
Number of subjects: 4
Study 9545890 — intervention group
Group type: COMPARATOR
Intervention: Prisma TPH/UB3
Number of subjects: 4
Study 9545890 — intervention group
Group type: COMPARATOR
Intervention: Prisma TPH/ProBond
Number of subjects: 4
Study 8465834 — intervention group
Group type: EXPERIMENTAL
Intervention: MRFIT hypertensive patients with diuretic-based pharmacologic regimen
Number of subjects: 5524
Study 8465834 — intervention group
Group type: EXPERIMENTAL
Intervention: Average on-treatment DBP < 95 mm Hg in MRFIT
Number of subjects: 5524
Study 8465834 — intervention group
Group type: COMPARATOR
Intervention: Baseline and 1-year change in creatinine level in TOMHS
Number of subjects: 5524
Study 8465834 — intervention group
Group type: COMPARATOR
Intervention: MRFIT screenees
Number of subjects: 5524
Study 8465834 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-year change in creatinine in MRFIT hypertensive patients
Number of subjects: 5524
Study 3941301 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnotherapy
Number of subjects: 100
Study 3941301 — intervention group
Group type: COMPARATOR
Intervention: Control group (no hypnotherapy)
Number of subjects: 100
Study 30171785 — intervention group
Group type: EXPERIMENTAL
Intervention: First-grade schooling group
Number of subjects: 91
Study 30171785 — intervention group
Group type: EXPERIMENTAL
Intervention: WM training group
Number of subjects: 91
Study 30171785 — intervention group
Group type: EXPERIMENTAL
Intervention: IC training group
Number of subjects: 91
Study 30171785 — intervention group
Group type: COMPARATOR
Intervention: Business-as-usual kindergarten control group
Number of subjects: 91
Study 28441094 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotavirus vaccine
Number of subjects: 63225
Study 28441094 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63225
Study 26220816 — intervention group
Group type: EXPERIMENTAL
Intervention: Short messaging service text
Number of subjects: 20
Study 26220816 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal digital assistant (e.g., iPod Touch)
Number of subjects: 20
Study 23017329 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (0.1 mg/45 kg)
Number of subjects: 10
Study 23017329 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 21307764 — intervention group
Group type: EXPERIMENTAL
Intervention: Peristaltic pneumatic compression
Number of subjects: 70
Study 19277473 — intervention group
Group type: EXPERIMENTAL
Intervention: New surgical methods and procedures tested in surgical RCTs
Number of subjects: 0
Study 19277473 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical RCTs conducted in six surgical trial centers
Number of subjects: 0
Study 17140874 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental practice and CIMT
Number of subjects: 4
Study 17140874 — intervention group
Group type: EXPERIMENTAL
Intervention: CIMT
Number of subjects: 4
Study 17140874 — intervention group
Group type: EXPERIMENTAL
Intervention: CIMT plus mental practice
Number of subjects: 4
Study 17140874 — intervention group
Group type: COMPARATOR
Intervention: Mental practice alone
Number of subjects: 4
Study 12771298 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcijex injected directly into the PTG (2 microg/ml preparation)
Number of subjects: 19
Study 12771298 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcijex injected directly into the PTG (1 microg/ml preparation)
Number of subjects: 19
Study 12771298 — intervention group
Group type: EXPERIMENTAL
Intervention: PCIT (both groups)
Number of subjects: 19
Study 11580868 — intervention group
Group type: EXPERIMENTAL
Intervention: Nerve growth factor (NGF)
Number of subjects: 42
Study 11580868 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurotrophin-3 (NT-3)
Number of subjects: 42
Study 9226488 — intervention group
Group type: EXPERIMENTAL
Intervention: Very Low Calorie Diet (VLCD) 1764 kJ/d (420 kcal/d)
Number of subjects: 81
Study 9226488 — intervention group
Group type: COMPARATOR
Intervention: Balanced hypocaloric diet of 6720 kJ/d (1600 kcal/d)
Number of subjects: 81
Study 9226488 — intervention group
Group type: EXPERIMENTAL
Intervention: Balanced hypocaloric diet with 1 MJ of VLCD (group C)
Number of subjects: 81
Study 9226488 — intervention group
Group type: EXPERIMENTAL
Intervention: Balanced hypocaloric diet without VLCD (group B)
Number of subjects: 81
Study 9226488 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 81
Study 9226488 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition powder (1 MJ) taken freely
Number of subjects: 81
Study 8427339 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (20 g)
Number of subjects: 0
Study 8427339 — intervention group
Group type: COMPARATOR
Intervention: Safflower oil (control)
Number of subjects: 0
Study 3296854 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural anesthesia and analgesia (EAA)
Number of subjects: 53
Study 3296854 — intervention group
Group type: COMPARATOR
Intervention: Standard anesthetic and analgesic techniques without EAA
Number of subjects: 53